Aim Immunotech Inc. (DE:HXB)
XASE:HXB
HXB Stock Chart & Stats
€6.10
--
Market closed
€6.10
--
Day’s Range― - ―
52-Week Range€6.09 - €6.09
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.79M
Enterprise Value€145.96K
Total Cash (Recent Filing)€5.88M
Total Debt (Recent Filing)€4.57M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Aug 18, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding14,563,515
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.54Price Target Upside-25.51% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.13
Revenue Forecast (FY)€85.97K
Bulls Say, Bears Say
Bulls Say
Pancreatic Cancer Clinical ProgressDurable clinical signals in late-stage pancreatic cancer, KOL engagement and an ongoing Phase 2 combination with AstraZeneca’s Imfinzi indicate external scientific validation. Sustained positive clinical data can underpin regulatory filings, partner interest and a pathway to commercialization in a high-unmet-need indication.
Orphan Designations And Ebola Preclinical DataOrphan designations and strong preclinical antiviral efficacy expand the strategic use case for Ampligen beyond oncology into biodefense and emerging viral threats. Those regulatory incentives and differentiated mechanism (TLR3 agonist) can enable expedited pathways, niche market exclusivity and non-dilutive government or grant funding opportunities.
Demonstrated Access To CapitalRepeated successful capital raises show the company can source institutional funding to finance clinical manufacturing and trials. This ability to access equity markets and structured financings is a durable operational capability that supports progress of clinical programs while management pursues data-driven value inflection points.
Bears Say
Minimal Revenue BaseThe company's revenue run-rate is negligible and profitability remains deeply negative, reflecting an early-stage commercial profile. Over a multi-month horizon this weak top line limits organic funding, raises execution risk for scaling programs, and makes progress heavily dependent on external financing or partnerships.
Persistent High Cash BurnSustained negative OCF and FCF demonstrate material cash burn to support R&D and trials. Without material revenue or milestone receipts, continuing operations will require repeated financing, compressing runway and elevating the execution risk that clinical programs must reach data milestones to avoid funding shortfalls.
Structural Dilution And Financing DependenceManagement’s frequent equity, warrant inducements and removal of ATM caps show a structural reliance on dilutive financings. Over months this can materially dilute existing shareholders, alter capital structure dynamics and reduce alignment, making long-term shareholder value contingent on outsized clinical or partnership successes.
AIM ImmunoTech News
HXB FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was €6.09 and its highest was €6.09 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is €5.79M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 66 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Currently, no data Available
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Overvalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of €0.235 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate is -0.15.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 14,563,515 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in DE:HXB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
HXB Stock 12 Month Forecast
Average Price Target
€4.54
▼(-25.51% Downside)
Technical Analysis
Options Prices
Currently, No data available
---